Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342563 · ClinicalTrials.gov registry record · Phase 2
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
A Phase 2 study of Alcoholism, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT00342563: Completed Phase 2 study of Alcoholism, sponsored by Yale University.
NCT00342563 is a Phase 2 study of Alcoholism that has completed, run by Yale University. The registered enrollment target is 136 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342563, a Phase 2 study of Alcoholism, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients. We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecamylamine will be effective in reducing both alcohol consumption and smoking in a subset of alcoholics who also smoke.
Primary Outcome
Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG mecamylamine
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2004-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT00342563 record still lists
NCT00342563 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00342563 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00342563 about?
NCT00342563 is a clinical study titled "Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients". The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients. We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecam...
What is the current status of trial NCT00342563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2004-05. Estimated completion is 2015-07.
What conditions does trial NCT00342563 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00342563?
The interventions under investigation include: Placebo (DRUG), mecamylamine (DRUG).
Who is sponsoring clinical trial NCT00342563?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00342563 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00342563's enrollment target sits among peer trials
136 29th of 65 higher than 37 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia